Literature DB >> 19914678

HER-2 amplification is highly homogenous in gastric cancer.

Michael Bilous, Robert Y Osamura, J Rüschoff, Marc van de Vijver, Wedad Hanna, Frederique Penault-Llorca, Patrick Roche.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19914678     DOI： 10.1016/j.humpath.2009.10.006

Source DB:  PubMed          Journal:  Hum Pathol        ISSN： 0046-8177            Impact factor:   3.466


× No keyword cloud information.
  16 in total

1.  HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis.

Authors:  Zhi Peng; Jianling Zou; Xiaotian Zhang; Yehong Yang; Jing Gao; Yilin Li; Yanyan Li; Lin Shen
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

Review 2.  Current status of novel agents in advanced gastroesophageal adenocarcinoma.

Authors:  Nishi Kothari; Khaldoun Almhanna
Journal:  J Gastrointest Oncol       Date:  2015-02

3.  Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.

Authors:  Nicola Personeni; Marina Baretti; Silvia Bozzarelli; Paola Spaggiari; Luca Rubino; Maria Chiara Tronconi; Uberto Fumagalli Romario; Riccardo Rosati; Laura Giordano; Massimo Roncalli; Armando Santoro; Lorenza Rimassa
Journal:  Gastric Cancer       Date:  2016-08-16       Impact factor: 7.370

4.  Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.

Authors:  Harry H Yoon; Qian Shi; William R Sukov; Anne E Wiktor; Maliha Khan; Christopher A Sattler; Axel Grothey; Tsung-Teh Wu; Robert B Diasio; Robert B Jenkins; Frank A Sinicrope
Journal:  Clin Cancer Res       Date:  2012-01-15       Impact factor: 12.531

Review 5.  HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice.

Authors:  Federica Grillo; Matteo Fassan; Francesca Sarocchi; Roberto Fiocca; Luca Mastracci
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

6.  Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma.

Authors:  Harry H Yoon; Qian Shi; William R Sukov; Mark A Lewis; Christopher A Sattler; Anne E Wiktor; Tsung-Teh Wu; Robert B Diasio; Robert B Jenkins; Frank A Sinicrope
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

7.  Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.

Authors:  Cathy B Moelans; Paul J van Diest; Anya N A Milne; G Johan A Offerhaus
Journal:  Patholog Res Int       Date:  2010-12-06

8.  Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.

Authors:  Elena García-García; Carlos Gómez-Martín; Bárbara Angulo; Esther Conde; Ana Suárez-Gauthier; Magdalena Adrados; Cristian Perna; José Luis Rodríguez-Peralto; Manuel Hidalgo; Fernando López-Ríos
Journal:  Histopathology       Date:  2011-07       Impact factor: 5.087

9.  Targeted therapy for esophagogastric cancers: a review.

Authors:  Muhammad A Khattak; Hilary L Martin; Christos S Karapetis
Journal:  Onco Targets Ther       Date:  2012-05-21       Impact factor: 4.147

10.  Her2/neu testing in gastric cancer: evaluating the risk of sampling errors.

Authors:  V S Warneke; H-M Behrens; C Böger; T Becker; F Lordick; M P A Ebert; C Röcken
Journal:  Ann Oncol       Date:  2012-11-08       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.